Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children  by Woodard, Paul et al.
From 1Am
Cance
Child
4Nati
for In
wauke
Medic
of W
Child
Canad
and 10
cer C
Financial d
Correspon
ter fo
Medic
C 550
Received J
 2011 Am
1083-8791
doi:10.101Unrelated Donor Bone Marrow Transplantation
for Myelodysplastic Syndrome in Children
Paul Woodard,1 Paul A. Carpenter,2 Stella M. Davies,3 Thomas G. Gross,4 Wensheng He,5
Mei-Jie Zhang,5 Biljana N. Horn,6 David A. Margolis,7 John P. Perentesis,3
Jean E. Sanders,2 Kirk R. Schultz,8 Adriana Seber,9 William G. Woods,10 Mary Eapen5We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation
(BMT) for myelodysplastic syndrome (MDS) in 118 patients aged #18 years. Forty-six patients had refrac-
tory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess
blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative
risk [RR] 3.29, P 5 .002). Disease recurrence was more likely with advanced stages of MDS at the time of
BMT: RAEB (RR 6.50, P5 .01) or RAEB-t (RR 11.00, P5 .004). Treatment failure (recurrent disease or death
from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT
(RR 2.79, P5 .001) and in those with RAEB-t (RR 2.38, P5 .02). Secondary MDS or chemotherapy prior to
BMTwas not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not
associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched
unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and
RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should
be offered as first-line therapy, and children with RC can be expected to have the best outcome.
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Myelodysplastic syndrome (MDS) in childhood is
a rare disorder, with an estimated incidence of 3.2 per
million [1]. Childhood MDS responds poorly to acute
myeloid leukemia (AML)-type chemotherapy, and
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6/j.bbmt.2010.08.016known curative treatment option. However, apart from
juvenile myelomonocytic syndrome (JMML) or MDS
transformed toAML, there exists fewreports for children
with MDS after allogeneic HCT. Disease-free survival
(DFS) rates support HCT when an HLA-matched sib-
ling donor is available [2,3]. Given that only a third of
patients have an HLA-matched sibling, it is clinically
relevant to understand the outcomes and risk factors
associated with DFS after unrelated donor HCT. Thus
far, reports of unrelated donor HCT for children with
MDS have been limited by sample size, heterogeneity
of donor type, and the inclusion of adults with
MDS [4-6]. Furthermore, the standard International
Prognostic Scoring System (IPSS) for adults with MDS
is of little prognostic value in children [7]. Therefore,
we examined outcomes after unrelated donor HCT for
MDSinpatients aged#18years after applyinga standard
scoring system appropriate for childhoodMDSbased on
morphology as recommendedby theEuropeanWorking
Group for Myelodysplasia (EWOG-MDS) [7].PATIENTS AND METHODS
Patients
Patients with MDS aged\18 years at transplanta-
tion who received a bone marrow (BM) graft from an723
724 Biol Blood Marrow Transplant 17:723-728, 2011P. Woodard et al.unrelated adult donor in the United States were iden-
tified from the Center for International Blood
and Marrow Transplant Research (CIBMTR). The
CIBMTR collects patient, disease, and transplant
characteristics on all unrelated donor transplantations
in the United States. All patients are followed longitu-
dinally annually. MDS subtypes included refractory
cytopenia (RC), refractory anemia with excess blasts
(RAEB), or refractory anemia with excess blasts in
transformation (RAEB-t), and were assigned retro-
spectively by the CIBMTR according to the European
Group for Childhood MDS (EWOG-MDS) criteria
[7]. Donor-recipient HLA-match was considered at
the allele level for HLA-A, -B, -C, -DRB1. Donor
and recipients were considered to be matched when
matched at HLA-A, -B, -C, -DRB1 and mismatched
when a mismatch existed at 1 or 2 loci. Excluded
were patients who had received prior autologous or
allogeneic BMT, peripheral blood progenitor cell
(PBPCs), or cord blood (CB) transplant, those with
Down syndrome, Fanconi anemia, JMML, or MDS
with progression to AML. This study was approved
by the institutional review board of the Medical
College of Wisconsin.
Endpoints
Neutrophil recovery was defined as the first of 3
consecutive days with an absolute neutrophil count
(ANC) $0.5  109/L. Patients who failed to achieve
ANC $0.5  109/L within 28 days after HCT or ex-
perienced a sustained decline in ANC (\0.5  109/L)
after initial recovery were considered to have graft
failure. Platelet recovery was defined as the first of 7
consecutive days with an unsupported platelet count
$20 109/L. Acute and chronic graft-versus-host dis-
ease (aGVHD, cGVHD)were diagnosed and classified
by the transplant center according to published criteria
[8,9]. Recurrent disease after BMT was defined by the
evolution of RC to RAEB or for RAEB/RAEB-t by the
recurrence of blasts or progression to AML. Death
from any cause in the absence of recurrent disease
was defined as transplant-related mortality (TRM).
All surviving patients were censored at last follow-up.
Statistical Analysis
The probabilities of neutrophil and platelet recov-
ery, aGVHD and cGVHD, TRM, and disease recur-
rence were calculated using the cumulative incidence
function estimator [10]. For neutrophil and platelet re-
covery and GVHD, death was the competing event.
For TRM, recurrence was the competing event, and
for recurrence, TRM the competing event. The prob-
ability of DFS was calculated using the Kaplan-Meier
estimator [11]. The 95% confidence intervals (CI)
were calculated using log transformation. The follow-
ing variables were considered in multivariate analysis:gender, age at transplantation (#10 versus.10 years),
disease status (RC versus RAEB versus RAEB-t), cyto-
genetics (monosomy 7 versus other abnormalities ver-
sus normal cytogenetics), de novo versus secondary
MDS, donor-recipient HLA match (matched versus
mismatched), year of transplantation (#1994 versus
.1994), and conditioning regimen (total body irradia-
tion [TBI]-containing versus chemotherapy-only reg-
imens). Multivariate models for aGVHD and
cGVHD, TRM, disease recurrence, and treatment
failure (inverse of DFS; recurrent disease or death
from any cause) were built using Cox regression and
a forward selection procedure [12]. Only variables
that attained a P value #.05 were retained in the final
multivariate model. All variables tested met the pro-
portionality assumption. All tests are 2-sided. Analyses
were performed with SAS version 9.1 (Cary, NC).RESULTS
There were 118 unrelated donor bone marrow
transplantations (BMT) for pediatric patients with
MDS in the United States between 1990 and 2005.
Patient, disease, and transplant characteristics are
shown in Table 1. The median age at BMT was 8
years. Approximately 40% of patients had RC and
60%, RAEB or RAEB-t at the time of BMT. For
each patient, the most advanced disease stage at any-
time prior to BMT was considered. Six patients with
RC at diagnosis progressed to RAEB, and 7 patients
with RAEB, at diagnosis progressed to RAEB-t before
BMT. Thirty-six patients (31%, n 5 9 RC, n 5 19
RAEB, and n5 8 RAEB-t) received chemotherapy be-
fore BMT. The median time from diagnosis to BMT
was 7 months for RC and 6 months for RAEB/
RAEB-t. Thirty patients (25%; 12 with RC, 15 with
RAEB, and 3 with RAEB-t) had secondary MDS that
resulted from chemotherapy and/or radiotherapy for
a prior malignancy (n5 18), or evolved from acquired
or congenital bone marrow failure (n5 11) or systemic
lupus erythematosus (n 5 1). Cytogenetic abnormali-
ties were identified in 64% of cases, and the most com-
mon abnormality was monosomy 7 (33%). A third of
BM grafts were T cell depleted. Transplant condition-
ing regimens were exclusively myeloablative, and ap-
proximately 70% of regimens contained TBI. The
median follow-up of surviving patients is 8 years.Neutrophil and Platelet Recovery
Most patients achieved hematopoietic recovery.
The day 28 cumulative incidence of neutrophil recov-
ery was 89% (95% CI 82-94), and the 6-month cumu-
lative incidence of platelet recovery was 74% (95% CI
65-81).
Table 1. Patient, Disease, and Transplant Characteristics
Variable Number (%)
Patients 118
Age at transplant, years
#5 30 (25)
6-10 38 (32)
11-18 50 (43)
Male 70 (59)
Performance score prior to
transplantation
<90% 20 (17)
90%-100% 91 (77)
Not reported 7 ( 6)
MDS classification (EWOG-MDS)
Refractory cytopenia 46 (39)
Refractory anemia with excess
blasts*
55 (47)
Refractory anemia with excess
blasts in transformation*
17 (14)
Interval from diagnosis to transplant,
months
#6 57 (48)
7-12 31 (26)
>12 30 (26)
Cytogenetics
Normal karyotype 27 (23)
Monosomy 7 ± other abnormalities 39 (33)
Complex karyotype
($3 abnormalities)
18 (15)
Other karyotypes 19 (16)
Not reported 15 (13)
Conditioning regimen
Total body irradiation +
cyclophosphamide
80 (68)
Total body irradiation + other 3 (3)
Busulfan + cyclophosphamide 30 (25)
Busulfan + other 4 (3)
Melphalan + other 1 (1)
Characteristics of patients N (%)
Graft-versus-host disease prophylaxis
T cell depletion 39 (33)
Cyclosporine alone 7 (6)
Cyclosporine + methotrexate 62 (52)
Tacrolimus + alone 1 (1)
Tacrolimus + methotrexate 9 (8)
Donor-recipient sex match
Male donor–male recipient 44 (37)
Male donor–female recipient 17 (14)
Female donor–male recipient 26 (22)
Female donor–female recipient 31 (26)
Donor-recipient HLA match
Matched at HLA-A, -B, -C, -DRB1 36 (31)
Mismatched at 1 or 2-loci 82 (69)
Donor-recipient cytomegalovirus
serostatus
Donor (2)–recipient (2) 43 (36)
Donor (2)–recipient (+) 19 (16)
Donor (+)–recipient (2) 30 (26)
Donor (+)–recipient (+) 23 (19)
Unknown 3 (3)
Year of transplant
1990-1994 22 (19)
1995-1999 63 (53)
2000-2005 33 (28)
Median (range) follow-up of survivors,
months
92 (3-195)
EWOG-MDS indicates European Working Group for Myelodysplasia.
*RC at diagnosis and progressed to RAEB prior to transplant: n 5 6;
RAEB at diagnosis and progressed to RAEB-t prior to transplant: n5 7.
Biol Blood Marrow Transplant 17:723-728, 2011 725Unrelated Donor BMT for Pediatric MDSGVHD
Fifty-five patients developed grade 2-4 aGVHD
(n 5 20 grade 2, n 5 24 grade 3, and n 5 11 grade 4).
Grade 2-4 aGVHD occurred more frequently after
non–T cell–depleted BMT (relative risk [RR] 2.33,
95%CI, 1.20-4.52, P5 .01). The day-100 probabilities
of grade 2-4 aGVHD were 55% (95% CI 44-66) and
26% (95% CI 14-41) after non–T cell–depleted BMT
andT cell–depleted BMT, respectively. Forty-five chil-
dren developed either limited (n 5 13) or extensive
(n 5 32) cGVHD. The 8-year cumulative incidence
of cGVHD was 40% (95% CI 31-50). Chronic
GVHD rates were higher after conditioning that in-
cluded TBI (RR 2.97, 95% CI 1.58-5.58, P\ .001),
in patients aged .10 years (RR 3.01, 95% CI 1.49-
6.04, P 5 .002), and transplantation period 1990-1994
(RR 3.14, 95% CI 1.44-6.89, P 5 .004).
TRM
Forty-eight deathsoccurred fromtransplant-related
complications that occurred mostly within the first year
after transplantation. In multivariate analysis, the only
factor associated with TRM was donor-recipient HLA
mismatch. Mismatched transplant recipients were
more likely to experience TRM (RR 3.29, 95% CI
1.54-7.03, P5 .002). TBI-containing conditioning reg-
imens were not associated with excess TRM (RR 0.68,
95% CI 0.34-1.39, P 5 .29). Secondary MDS was also
not associated with excess TRM (RR 0.63, 95% CI
0.31-1.30, P 5 .21). The relatively small numbers of
patients in the current analysis with secondary MDS
prevented us from examining for an effect by etiology
of secondary MDS. It is likely that in a larger cohort,
TRM rates may differ in patients with MDS secondary
to amalignant disease and those who developMDS sec-
ondary to aplastic anemia. The 1- and 8-year probabili-
ties of TRM after HLA-matched transplants were 13%
and 26%, respectively. Corresponding probabilities af-
ter HLA-mismatched transplants were 42% and 52%,
respectively.
Recurrent Disease
Recurrence was defined as morphologic evidence of
RAEB, RAEB-t, or AML after BMT. Twenty patients
had recurrent disease. Recurrent disease wasmore likely
when patients were in RAEB (RR 6.50, 95% CI 1.45-
29.03, P 5 .01) or RAEB-t (RR 11.00, 95% CI 2.13-
56.78, P 5 .004). The 8-year probability of recurrent
disease was 4% when BMT occurred for RC compared
to 23% and 29% when BMT occurred for RAEB and
RAEB-t, respectively (Figure 1). Risk of disease recur-
rencewas similar inpatientswith primary and secondary
MDS (RR1.14, 95%CI 0.34-3.80,P5 .84). Treatment
prior to BMT for patients with RAEB/RAEB-t was not
associated with higher relapse (RR 1.85, 95% CI 0.70-
4.88, P 5 .21). However, there were only 27 patients
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Figure 1. The 8-year probabilities of recurrent disease after BMT: 4%
when transplantation was performed for RC, 23% when transplantation
was performed for RAEB, and 29% for when transplantation was per-
formed for RAEB-T.
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dose chemotherapy. The development of acute (RR
0.42, 95% CI 0.14-1.30, P 5 .13) and cGVHD (RR
0.71, 95% CI 0.24-2.08, P 5 .53) was not associated
with disease recurrence posttransplant. Although the
risk of relapse with TBI-containing conditioning regi-
men appears to be lower, this did not reach statistical
significance in this analysis (RR 0.53, 95% CI 0.18-
1.62, P5 .27).
DFS
The probability of DFS is shown in Figures 2A and
B. Treatment failure (recurrent disease or death from
any cause; inverse of DFS) occurred in 68 patients.
Recipients of mismatched transplants (RR 2.79, 95%
CI 1.51-5.14,P5 .001) and those withRAEB-t at trans-
plantation (RR 2.38, 95% CI 1.17-4.84, P 5 .02) were
more likely to experience treatment failure. Secondary
MDS was not associated with higher treatment failure
(RR 0.67, 95% CI 0.36-1.26, P 5 .22). Chemotherapy
prior to transplantation was also not associated with
treatment failure (RR 0.87, 95% CI 0.49-1.53, P 5
.63). The causes of death are shown in Table 2. Early
death (within 100 days after BMT) occurred in 25
patients, and death beyond this period occurred in 41
patients. GVHD and veno-occlusive disease accounted
formost early deaths.Beyond the early period, recurrent
disease and GVHD were the most common causes.
MostGVHD-related deaths occurred aftermismatched
BMT.Pr
ob
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Figure 2. (A) The 8-year probabilities of disease-free survival after BMT:
57% for patients received matched BMT (matched at HLAA, B, C, DRB1),
33% for patients receivedmismatched BMT. (B) The 8-year probabilities of
disease-free survival after BMT: 51%when transplantationwas performed
for RC, 35% when transplantation was performed for RAEB, and 29% for
when transplantation was performed for RAEB-T.DISCUSSION
Sibling donor BMT has been used for many years
as a primary approach to treatment of MDS, with sur-
vival rates of approximately 70%. As most children
withMDS will not have a matched family donor, there
is increased interest in investigating whether unrelated
donor transplantation is a suitable alternative, espe-
cially for children with RC. In this report, we analyzeda large pediatric cohort with a median follow-up of 8
years after transplantation to determine outcomes of
unrelated donor BMT facilitated by theNationalMar-
row Donor Program in the United States, and to iden-
tify risk factors that predict for a successful outcome.
Disease status at transplantation and donor-recipient
matching are important predictors for a successful out-
come. Recurrent disease was more likely when disease
status had advanced beyond RC. Other factors such as
pretransplant chemotherapy, secondaryMDS, and cyto-
genetic abnormality were not associated with disease
recurrence TRM or DFS. The relatively few patients
(n 5 18) with complex cytogenetic abnormalities in the
current analysis may have prevented us from detecting
an effect of this generally considered high-risk feature
on disease recurrence and DFS. Similarly, the relatively
small number of patients in the current analysis may
have prevented us from detecting an effect of pretrans-
plant chemotherapy or secondary MDS on TRM and
DFS.
TRM was higher after mismatched BMT, and the
effect was independent of transplantation period. The
transplants reported herein span over a decade, and do-
nor selection practices have evolved, themost important
being the definition of an appropriately matched donor
as one who is matched at HLA-A, -B, -C, -DRB1 with
allele-level HLA typing [13]. Most donor-recipient
Table 2. Causes of Death
Cause of Death
Died within
100 Days after
Transplantation
(N 5 25)
Died after
100 Days
Posttransplantation
(N 5 41)
Primary disease 1 16
Graft failure 1 0
Infection 1 4
Interstitial pneumonia 2 1
Adult respiratory distress syndrome 0 2
Veno-occlusive disease 4 0
EBV-PTLD 1 0
Hemorrhage 2 1
Graft-versus-host disease 8 13
Organ Failures 4 2
Other, not specified 1 2
EBV-PTLD indicates Epstein-Barr virus-posttransplant lymphoprolifera-
tive disease.
Biol Blood Marrow Transplant 17:723-728, 2011 727Unrelated Donor BMT for Pediatric MDSpairs in this analysis were mismatched, with only about
a thirdof recipientswho receivedBMgrafts fromdonors
matched at HLA-A, -B, -C, -DRB1. Consequently,
rates of aGVHD and cGVHD were high and likely
contributed to morbidity and subsequent mortality.
Although donor-recipient HLA disparity was not asso-
ciated with higher risks of aGVHD in this analysis,
larger series have shown this to be true [13]. Year of
transplantation, a surrogate for donor-selection prac-
tices, was associatedwith higher cGVHD.We observed
an effect of transplant-conditioning regimen on risks of
cGVHD. In the current analysis, TBI-containing regi-
mens increased the risk of cGVHD, whereas reports in
adultswithMDSsuggestGVHDrateswere comparable
after TBI-and non–TBI-containing conditioning regi-
mens [14,15]. Although we do not have a satisfactory
explanation for this observation, TBI-containing regi-
mens were not associated with higher risks of TRM
and was suggestive for lower relapse risks, although
this did not reach statistical significance. Although
aGVHD was lower in recipients of T cell–depleted
transplants, TRM and DFS rates were not different in
recipients of T cell–depleted and non–T cell–depleted
transplants.
Recent advances in transplantation strategies such
as use of reduced intensity conditioning (RIC) regi-
mens and CB grafts have been employed for children
with MDS, and it remains to be seen whether the
observed success after myeloablative regimens and
unrelated donor BMT are comparable to that after
RIC or CB transplantation. Strahm and colleagues
[16] from the EWOG-MDS recently reported 3-year
event-free survival (EFS) of 74% among 19 children
with RC who received a uniform RIC regimen and un-
related donor HCT. Although 3 of 19 patients experi-
enced graft failure, 2 were rescued with CD341 cell
boosts. These results are encouraging, but longer
follow-up of surviving patients are needed as well as
validation in a larger cohort prior to widespread
adoption of RIC regimens for MDS in children.Umbilical CB grafts has also been used for MDS in
children [17,18]. In the largest series, describing 42
children with MDS (n 5 21 RC and n 5 21 RAEB/
RAEB-t), the 2-year probabilities of TRM and DFS
were 56% and 32%, respectively, after umbilical CB
transplantation [18]. The current analysis suggests
TRM is lower and DFS higher after matched BMT,
although only a direct comparison of outcomes after
transplantation of unrelated BM and umbilical CB
will aid clinicians to select the optimal graft type in
the absence of a HLA-matched sibling. Similarly,
only a direct comparison of the intensity of condition-
ing regimens used can satisfactorily address the ques-
tion of the optimal conditioning regimen. Given the
rarity of this disease in children, it may take several
more years before sufficient numbers of patients are
available for comparison of transplant conditioning
regimens and/or unrelated donor graft sources.
Our data support best results after unrelated donor
BMT when patients are transplanted in RC and when
the donor and recipient are matched at HLA-A, -B,
-C, and DRB1. If a matched unrelated donor is avail-
able, waiting for disease progression before proceeding
to transplantation will only increase the risk of recur-
rent disease. Therefore, unrelated donor BMT when
a matched donor is available should be offered to chil-
dren with MDS using the criteria currently used for
advocating transplantation for children with amatched
sibling donor. In the absence of a matched unrelated
donor, transplantation of unrelated umbilical CB
transplantation is a reasonable alternative if offered at
centers experienced in unrelated CB transplantation.ACKNOWLEDGMENTS
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